Iran is currently grappling with severe shortages of essential medicines and skyrocketing prices, exacerbating the healthcare crisis for many citizens. Reports indicate that life-saving treatments, including those for cancer and heart disease, are increasingly difficult to obtain. For example, the price of Xgeva, a bone cancer medication, surged from 15,000,000 rials ($9.38) to 420,000,000 rials ($262.50) in just two months. Similarly, the cost of Lantus insulin rose from 1,770,000 rials ($1.11) to 7,100,000 rials ($4.44), with some types exceeding 70,000,000 rials ($43.75). Patients have reported rationing of medications and delays in treatment due to these shortages. The situation is compounded by a lack of basic medical supplies, such as disposable gloves, and common medications like antidepressants. Meanwhile, diplomatic efforts to ease tensions with the United States have yielded limited results, leaving the economic pressures on ordinary Iranians unresolved.